Background
==========

Sarcomatoid changes are rarely seen in epithelial malignancy, which has been found in kidney, breast, esophagus, lung, kidney, and urinary bladder, carrying an ominous prognosis \[[@b1-amjcaserep-20-1225]\]. Malignant tumors with sarcomatoid changes have a 35% and 27%, 5-year disease specific and progression-free survival, respectively \[[@b2-amjcaserep-20-1225]\]. Sarcomatoid differentiation has been reported to occur in \>5% of all renal cell carcinomas (RCCs) \[[@b3-amjcaserep-20-1225]\]. Chromophobe renal cell carcinoma (ChRCC), which originates from distal convoluted tubules and cortical collecting ducts, is a distinct subtype of renal cell carcinoma \[[@b3-amjcaserep-20-1225]\], which accounts for 4% to 6% of renal cell carcinoma subtypes \[[@b4-amjcaserep-20-1225]\]. Most ChRCC have good prognosis, but sarcomatoid change is a poor prognostic factor. Sarcomatoid transformation from epithelioid elements were believed to be a process of malignant progression. Here we present a case of sarcomatoid ChRCC with undifferentiated pleomorphic sarcoma-like elements and review the clinicopathological characteristics of sarcomatoid ChRCC.

Case Report
===========

Clinical history
----------------

On April 14, 2016, a 63-year-old female complained of painless gross hematuria for 3 months without family history. Routine urine test showed that urinary protein was ++ and white blood cells were +++; serum CA153 was moderately elevated at 71.08 U/ml (normal \<28 U/mL). Ultrasonography and a computed tomography (CT) scan showed a mass in lower pole of the right kidney, measuring 13.4×15.4×11.4 cm. CT scan is shown in [Figure 1](#f1-amjcaserep-20-1225){ref-type="fig"}. Tissue samples are shown in [Figure 2](#f2-amjcaserep-20-1225){ref-type="fig"}. The patient underwent a right radical nephrectomy with lymph nodes dissection under general anesthetic. There was no evidence of recurrence and lymphadenopathy at 12 months after surgery.

Material and methods
--------------------

The resected specimens were fixed in 10% neutral buffered formalin, embedded in paraffin, sliced in 4-μm thick sections and stained with routine hematoxylin and eosin staining and viewed under light microscopy. Immunohistochemical staining was done using the EnVision 2-step method. The primary anti-cytokeratin, vimentin, CD68, CD117, Ki-67, EMA, E-cadherin, and CK7 were purchased from Fuzhou Maixin Company. Antigen repair and immunohistochemical staining steps were performed in strict accordance with kit instructions; the staining process was set using positive and negative control DAB color. According to the different parts of the antibody coloring, tumor cell cytoplasm, membrane, or nucleus was brown to determine positive.

Gross
-----

The surgically resected kidney was bisected to reveal a well encapsulated, colorful mass occupying the lower pole. The size of the mass is 14×10×7 cm. The cut surface was predominantly solid and colorful. The majority area of the tumor was tan-gray, along with areas of yellowish necrosis, hemorrhage, and a tan-white area in the lower portion ([Figure 1](#f1-amjcaserep-20-1225){ref-type="fig"}).

Histology and immunohistochemistry
----------------------------------

Microscopically, sections showed a biphasic malignant neoplasm with epithelial and sarcomatoid features. The tan-gray areas showed a typical ChRCC morphology, which consisted of large and polygonal cells with accentuated cell borders, abundant pale granular eosinophilic cytoplasm, a prominent perinuclear halo. Spindle sarcomatoid cells, which arranged in ill-defined fascicles storiform among the well differentiated epithelioid nests, were poorly differentiated with prominent nuclear pleo-morphism and dispersed tumor giant cells ([Figure 3](#f3-amjcaserep-20-1225){ref-type="fig"}).

The ChRCC cells were positive for epithelial membrane antigen EMA, pan-cytokeratin, CD117, CK7, CD10, and E-cadherin, but negative for vimentin. The sarcomatoid components were strongly stained for vimentin, and weakly stained for cytokeratin and EMA. CD68 staining showed a paranuclear dot-like pattern ([Figure 4](#f4-amjcaserep-20-1225){ref-type="fig"}). Ki-67 index was approximately 30% in the sarcomatoid area, whereas it was 2% in the ChRCC areas ([Table 1](#t1-amjcaserep-20-1225){ref-type="table"}).

Using morphology and immunophenotype, the sarcomatoid components, which have pleomorphic cells with CD68 para-nuclear dot-like stained and disorder tissue structure, are easily diagnosed as undifferentiated sarcoma.

Discussion
==========

ChRCC has been recognized as an uncommom subtype of RCC in humans for more than 30 years and was first described by Thoenes et al. in 1985 \[[@b5-amjcaserep-20-1225]\] it accounts for 5.9% of RCCs \[[@b2-amjcaserep-20-1225]\]. The 5-year and 10-year cancer-specific survival rates have been reported to be 78% to 100% and 80% to 90%, respectively \[[@b2-amjcaserep-20-1225]\]. However, sarcomatoid differentiation of ChRCC is generally associated with a worse prognosis. In a study of 101 patients with sarcomatoid RCC (88 with available follow-up), de Peralta-Venturina et al. \[[@b6-amjcaserep-20-1225]\] reported a cancer-specific survival rate at 5 years of 22%. Furthermore, the Akhtar et al. \[[@b7-amjcaserep-20-1225]\] study indicated that it might be the most common type with sarcomatoid transformation among all RCCs, and their study results showed that sarcomatoid differentiation was found in 6 of 11 cases (55%) in chromophobe renal carcinoma. In addition, metastatic ChRCC has been found to have a high incidence of sarcomatoid features (50%) \[[@b8-amjcaserep-20-1225]\]. But these studies still do not confirm a chromophobe connection in sarcomatoid renal cell carcinoma (SRCC), based on additional studies encompassing large numbers. The mechanism of sarcomatoid transformation is still largely unknown. But sarcomatoid carcinoma is widely accepted as being the result of malignant progression of a primary tumor. The sarcomatoid components are diverse, and can resemble fibrosarcoma, osteosarcoma, chondrosarcoma, malignant fibrous histiocytoma, or undifferentiated sarcoma \[[@b7-amjcaserep-20-1225]--[@b9-amjcaserep-20-1225]\]. The percentage of sarcomatoid component might be different from case to case. In some cases, it might be limited to a low percentage. In other cases, it might involve almost all areas \[[@b10-amjcaserep-20-1225]\]. Differential diagnosis includes the sarcoma aforementioned and collision tumor. The classic final diagnosis of sarcomatoid ChRCC depended on the presence of classic ChRCC and the sarcomatoid elements remained epithelial markers such as CK or EMA \[[@b11-amjcaserep-20-1225]\].

We searched the English literature in PubMed and found 7 cases of sarcomatoid ChRCC. The clinicopathological characters of these cases, including our present cases, are summarized in [Table 2](#t2-amjcaserep-20-1225){ref-type="table"} \[[@b4-amjcaserep-20-1225],[@b5-amjcaserep-20-1225],[@b10-amjcaserep-20-1225]--[@b15-amjcaserep-20-1225]\]. The patients, 4 male and 4 female, were aged from 40 to 77 years (median age was 67.5 years). Tumor size were mostly large, varying from 2.5 cm to 20 cm in the greatest dimension. The histologic type of sarcomatoid components varied from case to case, most presented as osteosarcoma (4 out of 8 cases), and 3 were spindle cell sarcoma without histological subtype. The prognosis was poor, but there were still 2 cases alive after 12 months ([Table 2](#t2-amjcaserep-20-1225){ref-type="table"})

Clinically, it is well known that sarcomatoid differentiation of RCC is correlated with a poorer prognosis. Accumulated data indicate that the percentage of sarcomatoid elements (over 50%), angio-invasion, and high TNM stage are correlated adversely with survival \[[@b6-amjcaserep-20-1225]\]. Metastatic SRCC remains a disease of poor prognosis and difficult to treat. Chemotherapy regimen and targeted therapies showed little activity in SRCC \[[@b16-amjcaserep-20-1225]\]. Renal cell cancer has previously been reported to show sensitivity to immunotherapy, indicating the possible advantage of immunomodulating therapies over standard treatment \[[@b17-amjcaserep-20-1225]\]. Prospective trials assessing new drugs, including immune checkpoint inhibitors, are currently ongoing study on improved SRCC survival \[[@b16-amjcaserep-20-1225]\].

In our literature review of sarcomatoid ChRCC cases, 5 cases were stage IV with metastasis, and 4 of these 5 cases died within several months. The high-grade clinical stage might be due to the high aggressive behavior of sarcomatoid elements.

Conclusions
===========

In summary, sarcomatoid ChRCC is an uncommon tumor characterized by a biphasic tumor with both classical epithelial components and sarcomatoid components. The prognosis for sarcomatoid ChRCC is worse than for classical ChRCC. It is important to recognize that the sarcomatoid changes of ChRCC has the potential to behave aggressively and to metastasize.
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![Computed tomography (CT) scan of lesion. Arrow: Soft tissue mass is seen below the right kidney, which of the size was 13.4×15.4×11.4 cm; Arrowhead: CT scan showed the case had a calcified area inside in soft tissue mass.](amjcaserep-20-1225-g001){#f1-amjcaserep-20-1225}

![Gross morphology. Cut section of the right kidney showed a well-demarcated large tumor with a variegated appearance.](amjcaserep-20-1225-g002){#f2-amjcaserep-20-1225}

![Hematoxylin and eosin stained section. The chromophobe renal cell carcinoma cells had eosinophilic to pale cytoplasm with accentuated cell borders. Nuclei are centrally located with wrinkled nuclear membranes. The spindle sarcomatoid cells were arranged in ill-defined fascicles or storiform with occasionally tumor giant cells. Original magnification 400×.](amjcaserep-20-1225-g003){#f3-amjcaserep-20-1225}

![Immunohistochemical features of the tumor. (**A**) Chromophobe renal cell carcinoma (ChRCC) components were strongly immunostained for pan CK, while sarcomatoid components were weakly immunostained. Original magnification 400×. (**B**) The ChRCC cells were strongly immnostained in the membrane, for CD117. Original magnification 400×. (**C**) The spindle cells were strongly positive for CD68 with a paranuclear dot-like pattern. Original magnification 400×. (**D**) The sarcomatoid area was strongly positive for vimentin. Original magnification 400×.](amjcaserep-20-1225-g004){#f4-amjcaserep-20-1225}

###### 

The immunohistochemical features of sarcomatoid chromophobe renal cell carcinoma.

  **Antibody**   **Clone**     **ChRCC**   **Sarcomatoid cells**
  -------------- ------------- ----------- -----------------------
  Cytokeratin    AE1/AE3       +++         \+
  EMA            E-29          +++         \+
  Vimentin       V9            −           +++
  CD117          YR145         +++         −
  CD68           KP1           +++         −
  CK7            OV-TL 12/30   −           \+
  E-cadherin     MX020         ++          −

ChRCC -- chromophobe renal cell carcinoma.

###### 

Clinical and morphologic features of sarcomatoid chromophobe renal cell carcinoma.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Author**                                          **Diagnosis time**   **Age Year/sex**   **Greatest dimension**   **TNM tage**   **Metastasis**                                                **Clinical behavior**   **Sarcomatoid components**
  --------------------------------------------------- -------------------- ------------------ ------------------------ -------------- ------------------------------------------------------------- ----------------------- ----------------------------------------------------------------------
  Itoh et al. \[[@b10-amjcaserep-20-1225]\]           Unknown              74/M               19.0                     T4NxM1         Intraabdominal, liver, colon, and pulmonary                   Died after 1 month      2/3 (osteosarcoma-like component)

  Viswanathan et al. \[[@b12-amjcaserep-20-1225]\]    Unknown              45/F               20.0                     T2NxM1         Liver, right kidney\                                          Died in 1 month         NA (spindle cells)
                                                                                                                                      Lung, 12 to L1 vertebrae                                                              

  Gong et al. \[[@b11-amjcaserep-20-1225]\]           Unknown              72/M               7.0                      T1bNxM1        lungs, peritoneum, the distal small intestine, psoas muscle   NA                      NA (spindle cells)

  Tanaka et al. \[[@b13-amjcaserep-20-1225]\]         Unknown              77/M               2.5                      T1aN0M0        None                                                          Alive after 12 months   NA (osteosarcoma component)

  Quiroga-Garza et al. \[[@b5-amjcaserep-20-1225]\]   2006                 63/F               6.0                      T1bN1M1        None                                                          Alive after 10 months   70% (osteosarcoma and chondrosarcoma components)

  Hes et al. \[[@b14-amjcaserep-20-1225]\]            Unknown              74/M               12.0                     T2bNXMX        None                                                          Died in 3.5 months      NA (osteosarcoma, chondrosarcoma, and rhabdomyoblastic components)

  Daga et al. \[[@b15-amjcaserep-20-1225]\]           2012                 40/F               16.0                     T2bN0M1        None                                                          Alive after 12 months   40--50% (pleomorphic spindle cells and fibrosarcoma-like components)

  Present case                                        2016                 63/F               14.0                     T2bN0M0        None                                                          Alive until now         20% (undifferentiated pleomorphic sarcoma)
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

M -- Male; F -- female; NA -- not available.
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